JP2025506667A - エモパミル結合タンパク質阻害剤及びその使用 - Google Patents
エモパミル結合タンパク質阻害剤及びその使用 Download PDFInfo
- Publication number
- JP2025506667A JP2025506667A JP2024547925A JP2024547925A JP2025506667A JP 2025506667 A JP2025506667 A JP 2025506667A JP 2024547925 A JP2024547925 A JP 2024547925A JP 2024547925 A JP2024547925 A JP 2024547925A JP 2025506667 A JP2025506667 A JP 2025506667A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- compound
- pharma
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263309923P | 2022-02-14 | 2022-02-14 | |
| US63/309,923 | 2022-02-14 | ||
| PCT/US2023/012879 WO2023154499A1 (en) | 2022-02-14 | 2023-02-13 | Emopamil-binding protein inhibitors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025506667A true JP2025506667A (ja) | 2025-03-13 |
| JP2025506667A5 JP2025506667A5 (cg-RX-API-DMAC10.html) | 2026-02-24 |
Family
ID=85505736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024547925A Pending JP2025506667A (ja) | 2022-02-14 | 2023-02-13 | エモパミル結合タンパク質阻害剤及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250152574A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4479384A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025506667A (cg-RX-API-DMAC10.html) |
| CN (1) | CN119731156A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023154499A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY40865A (es) * | 2023-08-23 | 2025-02-14 | Biogen Ma Inc | Inhibidores de la proteína de unión al emopamilo y usos de estos |
| EP4766448A1 (en) * | 2023-08-25 | 2026-07-01 | Biogen MA Inc. | EMOPAMIL-BINDING PROTEIN INHIBITORS AND THEIR USES |
| WO2025049419A1 (en) * | 2023-08-28 | 2025-03-06 | Genzyme Corporation | Pyrazolyl compounds as emopamil binding protein inhibitors |
| WO2026112292A1 (en) * | 2024-11-20 | 2026-05-28 | Convelo Therapeutics, Inc. | Spirocyclic compounds for use in promoting remyelination |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10082496B2 (en) * | 2014-09-10 | 2018-09-25 | Board Of Regents Of The University Of Texas System | Targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis |
| MA44037B1 (fr) * | 2016-06-06 | 2020-03-31 | Arena Pharm Inc | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci |
-
2023
- 2023-02-13 JP JP2024547925A patent/JP2025506667A/ja active Pending
- 2023-02-13 CN CN202380033932.3A patent/CN119731156A/zh active Pending
- 2023-02-13 WO PCT/US2023/012879 patent/WO2023154499A1/en not_active Ceased
- 2023-02-13 EP EP23709534.4A patent/EP4479384A1/en active Pending
- 2023-02-13 US US18/837,245 patent/US20250152574A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250152574A1 (en) | 2025-05-15 |
| EP4479384A1 (en) | 2024-12-25 |
| CN119731156A (zh) | 2025-03-28 |
| WO2023154499A1 (en) | 2023-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024525580A (ja) | Ｉｒａｋ４タンパク質の分解をターゲティングするための化合物 | |
| WO2023154499A1 (en) | Emopamil-binding protein inhibitors and uses thereof | |
| WO2020117626A1 (en) | 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels | |
| AU2018224488A1 (en) | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | |
| EP3377060A1 (en) | Pyrazole compounds and methods of making and using same | |
| WO2021119254A1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| JP2018510135A (ja) | ＲＯＲγＴ阻害剤としての置換ピラゾール化合物及びその使用 | |
| CN112543753A (zh) | 可用于治疗疼痛和炎症的茚衍生物 | |
| EP3436458A1 (en) | Fused pentacyclic imidazole derivatives as modulators of tnf activity | |
| JP2018531957A (ja) | ＲＯＲγＴ阻害薬としての置換二環式ピラゾール化合物及びその使用 | |
| JP2025524910A (ja) | エモパミル結合タンパク質阻害剤及びその使用 | |
| US12122750B2 (en) | AT2R antagonists and uses thereof | |
| JP2025508839A (ja) | エモパミル結合タンパク質阻害剤及びその使用 | |
| JP2025504889A (ja) | エモパミル結合タンパク質阻害剤及びその使用 | |
| TW202409039A (zh) | 依莫帕米結合蛋白抑制劑及其用途 | |
| WO2025043148A1 (en) | Emopamil-binding protein inhibitors and uses thereof | |
| WO2025049275A1 (en) | Emopamil-binding protein inhibitors and uses thereof | |
| EA052613B1 (ru) | Антагонисты at2r и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260213 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260213 |